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SUMMARY
Both Eurotransplant (ET) and the US use the lung allocation score (LAS)
to allocate donor lungs. In 2015, the US implemented a new algorithm for
calculating the score while ET has fine-tuned the original model using
business rules. A comparison of both models in a contemporary patient
cohort was performed. The rank positions and the correlation between
both scores were calculated for all patients on the active waiting list in ET.
On February 6th 2017, 581 patients were actively listed on the lung trans-
plant waiting list. The median LAS values were 32.56 and 32.70 in ET and
the US, respectively. The overall correlation coefficient between both scores
was 0.71. Forty-three per cent of the patients had a < 2 point change in
their LAS. US LAS was more than two points lower for 41% and more
than two points higher for 16% of the patients. Median ranks and the
90th percentiles for all diagnosis groups did not differ between both scores.
Implementing the 2015 US LAS model would not significantly alter the
current waiting list in ET.
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Introduction
In May 2005, the lung allocation score (LAS) was imple-
mented in the US. This allocation system replaced a
scheme solely based on waiting time. There were three
objectives: reduce the number of deaths on the lung
transplant waiting list; increase the survival benefit for
lung recipients and ensure the efficient and equitable
allocation of lungs to transplant candidates [1].
Germany was the first country to adopt the LAS on
December 10, 2011; the Netherlands followed on April
22, 2014. These countries implemented the US LAS
model from 2008 that incorporates the current and
change of partial pressure of carbon dioxide. The Ger-
man experience after introduction of the LAS was fairly
similar to the US with an increase in transplants for
patients with restrictive lung diseases and critically ill
patients. A 26% reduction in waiting list mortality, and
an improved 1-year survival post-transplant rate from
76% to 81% was observed [2].
Despite the fact that the LAS had been up and running
in the US since 2005, starting the LAS scheme in the
Eurotransplant (ET) countries was associated with two
areas of uncertainty. Firstly, with its urgency driven allo-
cation scheme, Germany and the Netherlands already
had an urgency system in place to minimize waiting list
mortality. A patient who would fulfil High Urgent (HU)
criteria in the old scheme, and hence would subsequently
be prioritized over elective patients, would not necessar-
ily receive high LAS values. Secondly, in the era before
LAS implementation, the German patients were sicker
compared to those from the US, with 18% on ventilator
support, and 7% on extra corporeal life support (ECLS),
as opposed to 5.7% and 1.3% in the US [3–5]. As
patients on ECLS were not accounted for in the LAS,
already from the start specific business rules were intro-
duced in ET to solve this specific European situation.
This report contains a detailed description of these rules.
In February 2015, the US has implemented an update
of the LAS to better cope with patients with pulmonary
hypertension. Among other parameters, this new model
now included cardiac index, central venous pressure and
bilirubin.
The aim of this study is to compare the ET and the
updated US LAS in a ET wait list cohort.
Methods
Definitions
Throughout this report, the name ‘ET LAS’ model will
refer to the original LAS allocation scheme from 2005
with the incorporation of current partial pressure of
carbon dioxide and change of partial pressure of carbon
dioxide from 2008, with the inclusion of tailor-made
business rules (Table 1). While the ‘US LAS’ model is
the name for the LAS algorithm implemented in the US
in 2015 [6,7].
Both Germany and the Netherlands use the LAS sys-
tem for the national allocation of donor lungs, and in
this report they will be denoted as LAS countries.
Study population
All patients on the active waiting list in Germany and
the Netherlands on February 6, 2017 are included. This
is an arbitrary snapshot of the waiting list that reflects
the real-life situation in ET. Based on the algorithms
from both the ET LAS and the US LAS model, scores
are calculated for all patients using actual clinical infor-
mation available in the ET registry.
Upon listing for lung transplantation, and at regular
intervals thereafter, data on LAS parameters are submit-
ted to ET. Not all parameters needed for calculating the
US LAS were available, in those cases the US LAS score
was calculated using the US rules for treating missing
values [6].
Patients were classified into four groups depending
on their underlying disease: Group A, obstructive airway
diseases (e.g. chronic obstructive pulmonary disease
[COPD]); Group B, diseases of the pulmonary circula-
tion (e.g. idiopathic pulmonary arterial hypertension
(PAH)); Group C, suppurative lung diseases (e.g. cystic
fibrosis [CF]) and Group D, restrictive lung diseases
(e.g. pulmonary fibrosis).
2 Transplant International 2018;
ª 2018 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
Smits et al.
Exceptional LAS
In case the calculated LAS does not reflect the per-
ceived idea of transplant benefit for a particular trans-
plant candidate, it is possible to apply for an
exceptional LAS. This can be done by proposing an
alternative LAS value accompanied with a detailed
description of the underlying reasoning. Every proposal
for an exceptional LAS value will be evaluated by the
LAS review board (RB). In case the RB members agree
with the suggested exceptional LAS value, the value
will then be assigned to the patient, where the decision
of the RB members is binding. If the patient meets at
least one of the following criteria, a request for an
Exceptional LAS can be submitted: (i) Primary Pul-
monary Hypertension types 1 and 4 [8]; (ii)
Combined lung and non-renal transplant candidates;
(iii) Rare diseases; (iv) Specific situations in which the
LAS does not reflect the expected urgency and benefit.
In this waiting list cohort, none of the patients had an
exceptional LAS value.
Lung allocation policy changes
Prior to the introduction of the LAS in Germany, all
countries in ET exchanged donor lungs cross border with
high priority to patients in HU status. This HU status was
agreed upon by all countries and the access to the HU list
was controlled by a team of international auditors. In the
LAS era, Germany and the Netherlands no longer have
patients on an HU list, while this urgency tier system still
exists in the other countries. Upon LAS implementation
Table 1. Eurotransplant lung allocation score (LAS) business rules.
Ventilation/extra corporeal life support (ECLS)
If a candidate is on ECLS, the pre-ECLS settings on blood gases, oxygen and ventilator demands can be used for the LAS. If a
patient on ECLS has to be re-evaluated within 6 days after getting on ECLS, the pre-ECLS settings on blood gases, oxygen
and ventilator demands should be entered. If the re-evaluation takes place after at least 7 days or more, the current
ventilator requirements, oxygen demand and blood gases should be entered. If weaning attempts have been made, they
have to be documented.
Oxygen requirement at rest
The amount of oxygen needed to maintain adequate oxygen saturation of 90–92% at rest (l/min). An additional rule for high
flow oxygen therapy is introduced: High flow (HF)-oxygen therapy (=HF nasal cannula (HFNC)) is defined as an oxygen flow
>15 l/min. In patients with HF-oxygen therapy, oxygen saturation (SpO2) should be measured by pulse oximetry continuously
including documentation of SpO2 and oxygen fraction. In case of a titrated oxygen flow of more than 15 l/min, the oxygen
fraction should be entered. The maximum allowable value in the data form was reset from 26 to 15 l/min. Oxygen titration
also applies to ventilated patients.
PCO2
Blood gases for evaluation by LAS must adhere to all of the following criteria
-Blood gases should be of arterial or capillary origin;
-Blood gases at rest must be entered. Blood gases during or after exercise, or at night are not acceptable;
-Blood gases should be performed after titration of oxygen flow and adjusted by pulse oximetry to a target oxygen satura-
tion of 90–92%;
-Blood gases with a pO2 >60 mmHg (>8 KPa) should be repeated with oxygen titration to a target oxygen saturation of 90–
92%.
Six-minute walk distance
Six-minute walk distance obtained with a flow rate needed during exercise.
Bilirubin change
Candidates with pulmonary hypertension in hemodynamic decompensation are eligible for an exceptional LAS value under the
following rules: pulmonary arterial hypertension patients with a Cardiac Index <2 l/m2 and right atrial pressure >15 mmHg or
bilirubin increase by 50%/abnormal or a creatinine increase by >50%/abnormal, can be accepted with LAS value equivalent
to the 95th percentile of the waiting list.
Creatinine and creatinine change
A special rule for candidates with pulmonary hypertension in hemodynamic decompensation has been defined. See section on
bilirubin change.
Cardiac index
A special rule for candidates with pulmonary hypertension in hemodynamic decompensation has been defined. See section on
bilirubin change.
Central venous pressure (CVP)
A special rule for candidates with pulmonary hypertension in hemodynamic decompensation has been defined. See section on
bilirubin change.
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in Germany in December 2011, all countries within ET
also agreed to enter LAS data on all HU patients, arbitrar-
ily defined as those with a LAS of 50 or above, called ‘high
LAS’. As of that moment, the international exchange of
allografts for the sickest patient was redefined from a
sharing system for HU patients to sharing for patients
with a high LAS value. In contrast to the US, in the ET
LAS countries no local allocation was attempted first.
Statistics
For this study, the rank positions on the waiting list are
only based on the LAS values and do not take blood
group rules or other allocation factors like country bal-
ances into account. Rank positions are expressed as per-
centiles of the combined Dutch and Germany waiting
list, where the 90th percentile indicates that 10% of the
patients on the waiting list at that moment had a higher
LAS value.
The correlation between the ET LAS and the US LAS
is measured by Spearman’s rank correlation coefficient
and illustrated in scatter plots. Wilcoxon signed rank
test is performed for comparisons between medians.
Differences between groups were evaluated by Chi-
square test.
The change in LAS is obtained by subtracting the ET
LAS from the US LAS values. A Bland and Altman plot
is drawn to visualize agreement between the scores [9].
Differences between the ET LAS and the US LAS mod-
els are further shown by comparing median LAS values,
median rank positions and percentages of patients on
the active waiting list that have a calculated LAS value
above the 90th percentile, according to the ET LAS and
the US LAS.
For all analysis, a p value of P < 0.05 is considered
significant. All analyses are performed with SPSS v20.0.
Results
On February 6th 2017, 581 patients were listed with an
active urgency on the Dutch (N = 193) and German
(N = 388) lung transplant waiting list. None of these
patients had an exceptional LAS status. Demographic
statistics are provided in Table 2.
Correlation between the ET LAS and the US LAS
Scatter plots of the ET LAS and the US LAS percentiles
by diagnosis group are given in Fig. 1. Patients with a
US LAS higher than the ET LAS will appear above the
45 degree line and vice versa. The overall correlation
coefficient between ET LAS and US LAS is 0.71, for the
diagnosis groups A, B, C and D, a correlation of 0.42,
0.14, 0.75 and 0.72 is obtained, respectively.
Difference between the ET LAS and the US LAS
The mean change in LAS (US LAS – ET LAS) is 2.3,
with a standard deviation of 6.7 (Fig. 2). Figure 3 shows
that 43% of the patients had a < 2 point change in their
LAS. Compared to the ET LAS, the US LAS is more
than two points lower for 41% and more than two
points higher for 16% of the patients. The greatest
increase in LAS was seen in Group B patients, where
the US LAS was more than two points higher versus the
ET LAS in 50%. The greatest decrease was observed in
Group A patients, where 52% had a US LAS that is
more than two points lower compared to the ET LAS.
Table 2. Demographic statistics of the active waiting list
on February 6, 2017 in the Eurotransplant (ET) lung
allocation score (LAS) countries.
Variables
Number (%)/
median (IQR)
Age (years) 56 (49–61)
Body mass index 23 (20–26)
Diagnosis
Group A 338 (58)
Group B 26 (5)
Group C 60 (10)
Group D 102 (18)
Missing 55 (9)
Assistance level with daily activities
Total 6 (1)
Some 416 (72)
None 117 (20)
Missing 42 (7)
Diabetes 70 (12)
Continuous mechanical ventilation 4 (1)
Supplemental oxygen required at rest 282 (49)
Oxygen demand (l/min) 1.5 (1–2)
Forced vital capacity (%predicted) 46 (34–60)
Current PCO2 (mmHg) 45 (38–49)
Systolic pulmonary artery pressure
(mmHg)
34 (28–40)
pulmonary capillary wedge pressure
(mmHg)
10 (7–13)
Cardiac Index (l/min/m2) 2.9 (2.5–3.5)
Central Venous pressure (mmHg) 6 (4–9)
6-minute walk test distance (m) 230 (139–325)
Current Serum creatinine (mg/dl) 0.8 (0.6–0.9)
Current total bilirubin (mg/dl) 0.4 (0.3–0.5)
ET LAS 32.56 (32.52–34.69)
US LAS 32.70 (23.25–34.53)
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Median LAS by diagnosis grouping
There was a small but statistically significant lower med-
ian ET LAS of 32.56 compared to the median US LAS
of 32.70 (P < 0.0001).
Patients in Group A would obtain a lower median
LAS in the US model, the value drops from 32.10 to
29.21 for the ET LAS and the US LAS, respectively
(P < 0.0001), while patients in Group C would see an
increase in the median LAS in the US model, from
35.18 to 35.93 (P = 0.003) (Fig. 4).
Both for Group B and Group D, the median LAS val-
ues between the ET LAS and the US LAS did not differ.
For Group B patients, the ET LAS and US LAS were
34.80 and 37.25 (P = 0.32), for Group D these median
values were 35.20 for the ET LAS and 34.74 for the US
LAS (P = 0.79).
Percentage of transplant candidates with a LAS >90th
percentile
Both in the ET LAS and the US LAS, the group C was
the largest group with LAS values above the threshold
of the 90th percentile. 31.7% of the patients on the
waiting list with group C diagnosis had an ET LAS
value that placed them above the 90th percentile, fol-
lowed by 23.5%, 15.4% and 2.1% of the patients with
group D, B and A diagnosis, respectively (Table 3).
With a LAS calculated according to the US model, the
percentages of patients in each diagnosis group with
LAS above the 90th percentile differed, but these differ-
ences did not reach statistical significance. According to
the US LAS, the percentages of patients with a US LAS
high enough to be in the top 10% of the waiting list
was for Group A 2.4% (difference between ET LAS and
US LAS P = 0.79), for Group B patients 19.8%
(P = 0.72), for Group C 35% (P = 0.70) and for Group
D patients this percentage was 22.5% (P = 0.87).
Median ranking by diagnosis grouping
Figure 5 shows the distribution of the rank positions by
diagnosis group. When sorted by their ET LAS values,
patients in Group D scored highest with a median per-
centile of 79, followed by Group C with 78, Group B
with 76 and 40 for Group A patients). Following the
US LAS, the difference in median rank position accord-
ing to the ET and the US LAS did not reach a statisti-
cally significant difference. The median rank positions
according to the US LAS scheme were for Group A
patients at the 38th percentile (difference between ET
LAS and US LAS, P = 0.81), for Group B patients this
percentile was 85 (P = 0.29), for Group C patients it
was 82 (P = 0.19) and for Group D it was 77
(P = 0.79).
Figure 1 Scatter plot of ET and revised UNOS LAS by diagnosis
group for patients on the active waiting list on February 6, 2017 in
the eurotransplant LAS countries. Group A (Blue dot), Group B
(Green dot), Group C (Orange dot), Group D (Red dot). Spearman’s
rank correlation coefficient 0.71.
Figure 2 Scatter plot of change in LAS (US LAS minus ET LAS) by
mean LAS ((US LAS + ET LAS)/2) by diagnosis group for patients on
the active waiting list on February 6, 2017 in the Eurotransplant LAS
countries. Group A (Blue dot), Group B (Green dot), Group C
(Orange dot), Group D (Red dot).
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Differences between ET and US LAS variables
The differences between ET and US LAS at variable
level are listed in Tables S1–S3.
Discussion
This is the first study comparing the ET LAS and the
US LAS in a large European patient cohort. Both mod-
els were strongly correlated most closely for group C
and group D patients. For all diagnosis groups in ET,
switching from the ET LAS to the US LAS would not
impact statistically significant on the median ranking
position and the percentage of patients that would have
LAS values high enough to be placed above the 90th
percentile of the waiting list would not change.
The allocation of donor lungs is governed by the LAS
system in three countries in the world. Both Germany
and the Netherlands allocate donor lungs according to
the LAS 2008 model, while in the US an adapted model
of 2015 was implemented. There were several shortcom-
ings in the 2008 model; both the ET countries and the US
have dealt with these shortcomings in a different way.
One of the major aims of the US LAS 2015 revision
was to better address rapidly deteriorating PAH patients.
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Figure 3 Change in LAS by diagnosis
group (US LAS minus ET LAS).
Figure 4 Box plots of ET LAS and US LAS by diagnosis group. ET
LAS (green), US LAS (Blue).
Figure 5 Box plots of percentiles based on ET LAS and US LAS by
diagnosis group. ET LAS (green), US LAS (Blue).
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With the addition of the factors bilirubin, changes in
bilirubin and creatinine as well as the factors cardiac
index and central venous pressure, a higher acuity of the
patient can be mapped in the US LAS. The ET LAS does
not include these factors, but already from the start spe-
cial business rules were introduced in ET to come to a
system that would fit our population. There were several
reasons for doing so. In contrast to the US, the LAS
replaced an urgency tier system, where patients fulfilling
strict criteria could be listed as high urgent, and receive
priority upon an organ offer. Furthermore, the lung
transplant candidate population in ET in 2011 was sicker
compared to the patients on the list in the US in 2005.
And thirdly, the US LAS model did not – and still does
not – include a factor for patients on ECLS.
The results of the first 3 years of LAS in Germany
show that the ET LAS model works. We observed an
increase in transplants for idiopathic pulmonary fibrosis
(IPF) and critically ill patients; a 26% reduction in wait-
ing list mortality, and an improved 1-year survival post-
transplant rate from 76% to 81% [2]. Hence, when the
US implemented a new LAS model in 2015, there was
no urgent need to follow the US and also implement
this US LAS model.
The LAS model has been shown to accurately predict
waiting list survival for the average PAH patient
[10,11]. But identifying among these PAH candidates
those who are most in need would require additional
information like mean right arterial pressure and 6-
minute walk test distance [12]. In ET, we adopted for a
system that would allow a fast access to transplantation
only for PAH patients who deteriorated quickly by
granting them an exceptional LAS value; more specific
the 95th percentile is assigned in case of demonstrated
progressive right heart failure for PAH patients. The US
LAS has introduced parameters such as cardiac index,
central venous pressure and bilirubin to better cope
with all group B patients. This difference in approach
explains the low correlation between the ET LAS and
the US LAS for group B patients.
The lack of correlation between the ET LAS and
the US LAS for group A patients can be explained by
the reduced influence of increasing age as well as the
reduced impact of supplemental oxygen in the US LAS.
In addition, a systolic pulmonary artery pressure below
40 mmHg no longer influences the LAS for group A
patients which accounts for their lower US LAS values.
Since the introduction of LAS, the proportion of
patients transplanted while on ECLS has increased, both in
the US and in ET [13]. Although this is an unwanted effect
of an allocation scheme without waiting time, several cen-
tres report good outcome for their awake ECLS patients
due to expertise and quick access to transplantation [14–
19]. This latter condition is facilitated in ET by allowing
pre-ECLS blood gases to be used in the LAS calculation.
One of the shortcomings of the LAS 2008 model was
related to huge impact of the factor oxygen requirements.
In addition, there were no rules for patients requiring
high flow nasal cannula (HFNC) therapy [20]. In the US
LAS 2015 model, the influence of the factor oxygen in the
waiting list model is reduced and the factor is added to
the post-transplant model, both measures aimed at
diminishing the effect of oxygen administration. In ET,
the statistical model remained the same, but we defined
standard titration rules, introduced a lower maximal
allowed flow rate and defined special rules for patients on
HFNC therapy. This results in lower median oxygen
demand of 1.5 L in ET versus 4 L in the US (personal
communication, Dr. Winslow J, data analyst UNOS).
In the US LAS, change in partial pressure of carbon
dioxide impacts more strongly on LAS. This measure is
particularly beneficial for non-IPF group D patients. In
ET, we opted for not changing this factor as our
patients in group D are already well served by the cur-
rent LAS, instead we strictly defined and standardized
the criteria under which blood gas analysis and oxygen
titration should be performed.
A drawback of this study is related to the cross-
sectional study design. By arbitrarily choosing a snap-
shot of the lung transplant waiting list not all aspects of
the ET LAS model could be studied. In particular, this
study cohort did not contain any patients with an
exceptional LAS.
In conclusion, implementing the 2015 US LAS model
in ET would not significantly impact on the current
waiting list. Our data show that the ET LAS and the US
LAS are correlated and median ranking positions as well
as the top 10% of the waiting list are not different
according to both models. However, ET is currently col-
lecting additional parameters to build up a database
that will allow further improvement of the LAS system.
Table 3. Percentage of patients exceeding the 90th
percentile of the waiting list.
Diagnosis
Eurotransplant lung
allocation score (LAS), % US LAS, % P value
Group A 2.1 2.4 0.79
Group B 15.4 19.8 0.72
Group C 31.7 35.0 0.70
Group D 23.5 22.5 0.87
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